| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 9150.4 | 8853.3 | 7868.1 |
| Other income | 264.2 | 117.0 | 105.3 |
| Total income | 9414.6 | 8970.4 | 7973.4 |
| Profit before exceptional items & tax | 1555.3 | 1290.6 | 1206.8 |
| Exceptional items | 40.2 | 0.0 | 0.0 |
| Profit before tax | 1515.1 | 1290.6 | 1206.8 |
| Net profit | 1032.0 | 920.8 | 824.2 |
| Operating margin | 16.1% | 14.4% | 15.1% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +25.20% |
|---|---|
| Net profit, quarter on quarter | +12.10% |
| Revenue, year on year | +16.30% |
| Operating profit, year on year | +17.20% |
| Operating profit, quarter on quarter | +10.00% |
NSE results filing, NSE: AUROPHARMA. Figures extracted from the filing.
Aurobindo Pharma Ltd: key numbers
- Share price
- ₹1,712.00
- Market cap
- ₹99,433 Cr
- Revenue (annual)
- ₹33,653 Cr
- Net profit (annual)
- ₹3,505 Cr
- P/E (TTM)
- 25.2×Sector 50.4×
- Promoter holding
- 51.88%+0.06% QoQ
- FII holding
- 16.38%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Aurobindo Pharma Ltd
All →Aurobindo Pharma Regulatory Approval
Aurobindo Pharma received USFDA final approval for its first MDI product, Beclomethasone Dipropionate HFA Inhalation Aerosol. The US market for this segment is estimated at US$301 million.
Aurobindo Pharma Acquisition Worth ₹9.47 Cr
Aurobindo Pharma's subsidiary acquired A1 Biochem USA Inc for ₹9.47 Crore. This 100% acquisition expands its contract research and development services capabilities in the USA.
- Value
- ₹9.47 Cr
Aurobindo Pharma Merger & Restructuring Worth ₹9.5 Cr
Aurobindo Pharma's subsidiary, A1 Biochem Labs (India), invested USD 1,000,000 (approx. ₹9.5 Crore) to incorporate and capitalize a new US subsidiary, A1 Biochem USA Inc.
- Value
- ₹9.50 Cr
Aurobindo Pharma Business Update
Aurobindo Pharma announced that the US FDA inspection of its subsidiary Apitoria Pharma's Unit-IV concluded with zero observations. This signals continued regulatory compliance for the facility.
Aurobindo Pharma Earnings Call Transcript: Key Takeaways
Q1FY27 revenue grew 16% YoY to ₹9,150 Cr. EBITDA margin stood at 21% with PAT of ₹1,032 Cr. Focus remains on complex generics, Lannett integration, and biosimilar monetization.
- Call
- Guides 10% growth
Aurobindo Pharma Investor Presentation: Key Takeaways
Aurobindo reported strong Q1FY27 performance with revenue up 16.3% YoY to ₹9,150 Cr and PAT up 25.2% to ₹1,032 Cr, driven by US base business volume gains and European expansion.